相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
Christopher Sweeney et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
Chengfei Liu et al.
CANCER RESEARCH (2015)
Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer
Robert J. van Soest et al.
EUROPEAN UROLOGY (2015)
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
Nader Al Nakouzi et al.
EUROPEAN UROLOGY (2015)
Impact of Center Size and Experience on Outcomes in Head and Neck Cancer
June Corry et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
Edward Samuel James et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
H. H. Cheng et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations
Daan Joost De Maeseneer et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial†
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2014)
Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences
K-H Chang et al.
BRITISH JOURNAL OF CANCER (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Chengfei Liu et al.
CLINICAL CANCER RESEARCH (2014)
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
Michael T. Schweizer et al.
EUROPEAN UROLOGY (2014)
Emerging mechanisms of enzalutamide resistance in prostate cancer
Frank Claessens et al.
NATURE REVIEWS UROLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Steroid Receptors Aplenty in Prostate Cancer
Nima Sharifi
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model
H. G. Nguyen et al.
ONCOGENE (2014)
Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens
Chunyu Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Clinical Activity of Enzalutamide in Docetaxel-Naive and Docetaxel-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer
Rosa Nadal et al.
PROSTATE (2014)
Molecular pathways and targets in prostate cancer
Emma Shtivelman et al.
ONCOTARGET (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
Che-Kai Tsao et al.
THERAPEUTIC ADVANCES IN UROLOGY (2014)
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
Haley L. Bennett et al.
BJU INTERNATIONAL (2013)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth
Muralimohan Yepuru et al.
CLINICAL CANCER RESEARCH (2013)
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
R. J. van Soest et al.
EUROPEAN JOURNAL OF CANCER (2013)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2013)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Castration-Resistant Prostate Cancer: AUA Guideline
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2013)
Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
Yezi Zhu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
Nagalakshmi Nadiminty et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
Nima Sharifi
MOLECULAR ENDOCRINOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Ayesha A. Shafi et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Autophagy: a targetable linchpin of cancer cell metabolism
Robert D. Leone et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
J. Mezynski et al.
ANNALS OF ONCOLOGY (2012)
Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2012)
Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
Shinichi Yamashita et al.
NEOPLASIA (2012)
Autophagy as a therapeutic target in cancer
Ning Chen et al.
CANCER BIOLOGY & THERAPY (2011)
Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
Medha S. Darshan et al.
CANCER RESEARCH (2011)
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Changmeng Cai et al.
CANCER RESEARCH (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2011)
Ten Years of Docetaxel-Based Therapies in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis of 2244 Patients in 12 Randomized Clinical Trials
Ary Serpa Neto et al.
CLINICAL GENITOURINARY CANCER (2011)
Alternatively spliced androgen receptor variants
Scott M. Dehm et al.
ENDOCRINE-RELATED CANCER (2011)
Novel Membrane-associated Androgen Receptor Splice Variant Potentiates Proliferative and Survival Responses in Prostate Cancer Cells
Xi Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
Amanda J. O'Neill et al.
MOLECULAR CANCER (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
Emma Hornberg et al.
PLOS ONE (2011)
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Kai-Hsiung Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Resistance to Docetaxel-Induced Apoptosis in Prostate Cancer Cells by p38/p53/p21 Signaling
Lu Gan et al.
PROSTATE (2011)
Androgen receptor signaling and mutations in prostate cancer
Shahriar Koochekpour
ASIAN JOURNAL OF ANDROLOGY (2010)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
Guillaume Ploussard et al.
CANCER RESEARCH (2010)
A mutation in β-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line
Takahito Hara et al.
CELL BIOLOGY INTERNATIONAL (2010)
Guidelines for the management of castrate-resistant prostate cancer
Fred Saad et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2010)
Molecular cell biology of androgen receptor signalling
Nigel C. Bennett et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Systematic Structure-Function Analysis of Androgen Receptor Leu701 Mutants Explains the Properties of the Prostate Cancer Mutant L701H
Dennis J. van de Wijngaart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Shihua Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Induction of Clusterin by AKT-Role in Cytoprotection against Docetaxel in Prostate Tumor Cells
Bin Zhong et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Conformation of the Mineralocorticoid Receptor N-terminal Domain: Evidence for Induced and Stable Structure
Katharina Fischer et al.
MOLECULAR ENDOCRINOLOGY (2010)
The Rules of DNA Recognition by the Androgen Receptor
Sarah Denayer et al.
MOLECULAR ENDOCRINOLOGY (2010)
Increased expression of class III β-tubulin in castration-resistant human prostate cancer
S. Terry et al.
BRITISH JOURNAL OF CANCER (2009)
A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
Zhiyong Guo et al.
CANCER RESEARCH (2009)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Qianben Wang et al.
CELL (2009)
Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells
Jae Yeon Chun et al.
CLINICAL CANCER RESEARCH (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor:: A collapsed disordered conformation underlies structural plasticity and protein-induced folding
Derek N. Lavery et al.
BIOCHEMISTRY (2008)
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
Richard D. Sowery et al.
BJU INTERNATIONAL (2008)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel
Tristan M. Sissung et al.
CLINICAL CANCER RESEARCH (2008)
Coactivators and nuclear receptor transactivation
Irene M. Wolf et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Autophagy fights disease through cellular self-digestion
Noboru Mizushima et al.
NATURE (2008)
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer
Wennuan Liu et al.
NEOPLASIA (2008)
Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex
Hannelore V. Heemers et al.
ENDOCRINE REVIEWS (2007)
Autophagosome formation: Core machinery and adaptations
Zhiping Xie et al.
NATURE CELL BIOLOGY (2007)
Nonreceptor tyrosine kinases in prostate cancer
Yu-Ming Chang et al.
NEOPLASIA (2007)
Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity
Josep Domingo-Domenech et al.
CLINICAL CANCER RESEARCH (2006)
Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells
T Hara et al.
PROSTATE (2005)
PAR1-mediated NFκB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism
K Tantivejkul et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Clusterin inhibits apoptosis by interacting with activated Bax
HL Zhang et al.
NATURE CELL BIOLOGY (2005)
Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family
J Simard et al.
ENDOCRINE REVIEWS (2005)
Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: Results of the randomized trial SAKK 08/88
UE Studer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Suppression of constitutive and tumor necrosis factor α-induced nuclear factor (NF)-κB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells:: Correlation with down-regulation of NF-κB-responsive genes
S Shukla et al.
CLINICAL CANCER RESEARCH (2004)
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer
K Steketee et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Molecular biology of the androgen receptor
EP Gelmann
JOURNAL OF CLINICAL ONCOLOGY (2002)
Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation - Influence of structure-stabilizing solutes and protein-protein interactions
J Reid et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Nuclear receptor coregulators: multiple modes of modification
O Hermanson et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2002)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone
JS Sack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Cell biology - Autophagy as a regulated pathway of cellular degradation
DJ Klionsky et al.
SCIENCE (2000)
分享论文
